Summit Therapeutics Inc. or Alpine Immune Sciences, Inc.: Who Invests More in Innovation?

Biotech Giants' R&D Race: Summit vs. Alpine

__timestampAlpine Immune Sciences, Inc.Summit Therapeutics Inc.
Wednesday, January 1, 20141219954715635076
Thursday, January 1, 20151605400023943601
Friday, January 1, 20162331600023689111
Sunday, January 1, 20171062600041006114
Monday, January 1, 20182897000051379106
Tuesday, January 1, 20193584700032705593
Wednesday, January 1, 20202718500053274000
Friday, January 1, 20215874200085352000
Saturday, January 1, 20227024300051999000
Sunday, January 1, 20238090400059471000
Loading chart...

Infusing magic into the data realm

Investing in Innovation: A Tale of Two Biotech Companies

In the competitive world of biotechnology, innovation is the lifeblood of success. Over the past decade, Summit Therapeutics Inc. and Alpine Immune Sciences, Inc. have been at the forefront of this race, each investing heavily in research and development (R&D). From 2014 to 2023, Summit Therapeutics consistently outpaced Alpine Immune Sciences in R&D spending, peaking in 2021 with a 45% higher investment. However, Alpine Immune Sciences has shown remarkable growth, increasing its R&D expenses by over 560% from 2014 to 2023. This trend highlights a strategic shift towards innovation, positioning both companies as key players in the biotech industry. As they continue to push the boundaries of medical science, their commitment to R&D underscores the importance of innovation in driving future breakthroughs.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025